Meet the two treatments withdrawn from the market by the FDA for not working against omicron

La eliminación de los tratamientos evita exponer a los pacientes a efectos secundarios.
Elimination of treatments avoids exposing patients to side effects.

Photo: CHAIDEER MAHYUDDIN / Getty Images

EFE

For: EFE

The Food and Drug Administration withdrew from the market

two treatments on the list of approved drugs against covid-19 because they are not effective against the omicron variant.

The FDA reported that it withdrew its authorization for the use of Bamlanivimab and Etesevimab, from the pharmaceutical company Eli Lilly- and from REGEN-COV, made up of Casirivimab and Imdevimab, from Regeneron.

“The data show that these treatments are highly unlikely to be active against the omicron variant, which is expanding rapidly in the United States,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. .

As of now, these drugs “are no longer authorized for use in any US state, territory or jurisdiction”.

“In the future, if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments, their use in those regions could be authorized,” added Cavazzoni.

The omicron variant accounts for more than 99% of covid-19 cases in the United States, according to data from the Centers for Disease Control and Prevention (CDC).

The elimination of treatments “avoids exposing patients to side effects, such as reactions at the injection site or allergic reactions that can be potentially serious” in patients infected with omicron, explained the doctor.

The FDA recalled that there are several authorized treatments in the country that are expected to work against the omicron variant in the case of patients who are at risk of developing severe disease, citing among them Paxlovid, Sotrovimab, V eklury (Remdesivir) and Molnupiravir.

The agency followed the recommendation of a committee of the National Institutes of Health (NIH), which last week advised against the use of Eli Lilly therapies and Regeneron considering that they had a “significantly reduced” effect against omicron.

Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
CORONAVIRUS: Chinese businessman arrested on suspicion of test theft thumbnail

CORONAVIRUS: Chinese businessman arrested on suspicion of test theft

Trata-se de um cidadão do bem e contribuiu de forma significativa para estabelecer o laço de amizade entre Brasil e China. “Trata-se de um cidadão do bem e contribuiu de forma significativa para estabelecer o laço de amizade entre Brasil e China.” A declaração, em papel timbrado, é da Associação Chinesa do Brasil sobre o…
Read More
Tomato development is promoted by functional bacteria under salt stress conditions thumbnail

Tomato development is promoted by functional bacteria under salt stress conditions

Estudo identificou isolados de bacilos com propriedades funcionais para promover o crescimento das plantas de tomateiro em condições de estresse salino do solo.De 154 isolados inicialmente estudados, quatro foram selecionados e mostraram resposta positiva no aumento da altura da planta, pesos das raízes, parte aérea, teor de clorofila e diâmetro do caule. Um deles foi capaz…
Read More
Index Of News
Total
0
Share